Results 31 to 40 of about 677,925 (163)
Identification and characterisation of suppressors of synthetic lethality resulting from loss of SETD2 and WEE1 [PDF]
, 2018 Our lab has recently identified a conserved synthetic lethality between loss of SETD2-dependent H3K36 trimethylation and inhibition of WEE1 kinase (Pfister et al., 2015).
core +1 more source
Frontiers in Pharmacology, 2019 Esophageal squamous cell carcinoma (ESCC) is a common malignant diagnosed cancer with increasing incidence rate and few treatment options. As a specific small-molecule inhibitor of the Wee1 tyrosine kinase, AZD1775 has previously shown potent antitumor ...
Shuning Bi +5 more
doaj +1 more source
ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
The Journal of Clinical Investigation, 2023 WEE1 has emerged as an attractive target in epithelial ovarian cancer (EOC), but how EOC cells may alter their sensitivity to WEE1 inhibition remains unclear.
Jie Li +16 more
doaj +1 more source
WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia
Haematologica, 2020 T-cell acute lymphoblastic leukemias (T-ALLs) are aggressive and heterogeneous hematologic tumors resulting from the malignant transformation of T-cell progenitors.
Juncheng Hu +14 more
doaj +1 more source
Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
, 2021 Inhibitors of WEE1 and ATR kinases are considered promising for cancer treatment, either as monotherapy or in combination with chemo- or radiotherapy. Here, we addressed whether simultaneous inhibition of WEE1 and ATR might be advantageous.
Lilli T. E. Bay +6 more
core +1 more source
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer [PDF]
, 2020 Purpose Pancreatic cancer (PC) is one of the most lethal cancers worldwide, but there are currently no effective treatments. The DNA damage response (DDR) is under investigation for the development of novel anti-cancer drugs.
Bang, Ju-Hee +5 more
core +1 more source
Frontiers in Oncology, 2020 WEE1 is a cell cycle and DNA damage response kinase that is emerging as a therapeutic target for cancer. AZD1775 is a small molecule inhibitor of WEE1, currently in early phase clinical trials as a single agent and in combination with more conventional ...
Tamara B. Garcia +6 more
doaj +1 more source
Cell size-dependent regulation of Wee1 localization by Cdr2 cortical nodes
, 2017 Cell size control requires mechanisms that link cell growth with Cdk1 activity. In fission yeast, the protein kinase Cdr2 forms cortical nodes that include the Cdk1 inhibitor Wee1, along with the Wee1-inhibitory kinase Cdr1.
Uche Medoh +4 more
core +1 more source
Cancer Cell International, 2021 Background To explore the mechanism of LINC00470 in serum exosomes from glioma patients regulating the autophagy and proliferation of glioma cells. Methods Exosomes were extracted from glioma patients (GBM-exo).
Wenjia Ma +4 more
doaj +1 more source